• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024

    12/22/23 4:31:26 PM ET
    $EEX
    $OGI
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EEX alert in real time by email

    Indigenous Leaders Lead The Way In Cannabis Regulation

    The Indigenous Cannabis Industry Association (ICIA) recently hosted its first Indigenous Cannabis Regulators roundtable. The event took place last month during its second annual National Indigenous Cannabis Policy Summit in Washington D.C.

    The gathering brought together Indigenous Cannabis Regulators from Tribal Nations and Indigenous-led cannabis organizations across the country to discuss community-oriented approaches to hemp and cannabis regulation and equitable policy reform.

    "Through responsible, community-oriented planning, cannabis can provide economic benefits and professional development for Indigenous communities," Rob Pero, founder of ICIA said. "The annual Summit lays the foundation to take action, make our voices heard and exercise sovereignty in regulation."

    MJBiz Transitions: Emilie Lewis To Lead Strategic Marketing Efforts

    Trade show and media company Emerald Holding, Inc. (NYSE:EEX) announced that Emilie Lewis has been promoted to the senior vice president role, overseeing marketing, audience, and content strategy for Marijuana Business Daily. Lewis replaces Pam Moore, who opted to part ways with MJBiz in October.

    Before joining MJBiz, Lewis served as vice president of marketing for ASD Market Week, the largest portfolio owned by Emerald, which bought MJBiz on Dec. 31, 2021, the news outlet recently reported.

    In September 2022, Lewis assumed the position of vice president of marketing at Emerald, where she was responsible for managing ASD Market Week, IGES, Sports Licensing and Source Direct.

    Cannabis Board Shake-Ups

    In the meantime, three cannabis companies reported board changes.

    MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced on Friday that Miriam McDonald has resigned from her position on the board of directors. As a founding board member of MediPharm Labs McDonald has been instrumental in guiding the company through many strategic decisions including, a go-public transaction, establishing leadership in the pharmaceutical cannabis space and multiple strategic capital raises.

    With this change, MediPharm Labs will continue with five board members, including four independents. The reduction in the number of board members reflects the overall right-sizing of the business which the Company has aggressively undertaken in 2023.

    Rythmia Life Advancement Center, a medically licensed plant medicine-based transformational center, has appointed the renowned comedian Ron White to its board, joining Rev. Michael Bernard Beckwith, Jack Canfield, Martin Luther King III, Toni Ko, Earl Koskie, Dr. Jeff McNairy, César Millán, Gerard Armond Powell, Jerry Powell, Patrick Powell, Brandee Sabella and Kelly Slater.

    Lowell Farms Inc. (CSE:LOWL) (OTCQX:LOWLF) said on Thursday that Brian Shure is stepping down from the company's board for personal reasons.

    Two Cannabis Giants Name New CFOs

    Trulieve Cannabis Corp. (CSE:TRUL) (OTCQX:TCNNF) has named Wes Getman as its new chief financial officer, effective Jan. 1, 2024. Getman has over 25 years of experience in accounting and finance in both corporate and advisory roles for private and public companies including Blue Bird Corporation, Grant Thornton, and PricewaterhouseCoopers. Ryan Blust, who has been serving as interim CFO will resume his duties as vice president of finance, once Getman assumes the CFO role.

    Organigram Holdings Inc. (TSX:OGI) (NASDAQ:OGI) announced on Monday that Greg Guyatt CPA, CA, formerly of Phoena Holdings Inc., has been appointed CFO, effective Jan. 8, 2024. Guyatt will lead Organigram's finance and IT divisions and will report directly to Beena Goldenberg, Organigram's CEO.

    Other Top Appointments In The Space

    Motif Labs, a Canadian cannabis company behind brands including Boxhot, DEBUNK and Boondocks announced recently the appointment of Andrew Litt as the company’s first chief manufacturing officer. Litt is a biochemical engineer whose career in the Canadian automotive sector spans two decades, including experience with the Toyota Production System. Most recently, he served as the General Manager of Brose Canada Inc., a German-based automotive pioneer.

    Innocan Pharma Corporation (CSE:INNO) (FSE: IP4) (OTCQB: INNPF) announced the establishment of a specialized team to prepare the company’s submission to the United States Food and Drug Administration for the human application of its LPT CBD platform.

    The team is comprised of accomplished drug development and drug approval experts, with specific experience in pharmacology, toxicology, clinical trials, and successful interaction with the FDA.

    The three-member team includes:

    Dr. Robert B. Raffa, PhD – an adjunct professor at the University of Arizona College of Pharmacy and professor emeritus at Temple University School of Pharmacy.

    Dr. Kory J. Engelke, PhD, DABT, brings more than 26 years of drug development/regulatory experience. He is an experienced pharmacologist and board-certified toxicologist with demonstrated proficiency in the design, implementation, interpretation, reporting, and defense of nonclinical and clinical studies and strategies to worldwide regulatory bodies and potential business partners.

    Dr. Joseph V. Pergolizzi Jr., MD, the co-founder and chief operating officer of NEMA Research Inc. and a senior partner at Naples Anesthesia and Pain Associates, Inc. Pergolizzi is an internationally renowned perioperative and pain specialist, well-versed in the multiplicity of issues confronting patients and caregivers in acute and chronic pain.

    Related News

    • Cannabis Movers & Shakers: Delaware’s New Marijuana Commissioner And Latest Industry Appointments
    • Cannabis Movers & Shakers: Item 9 Labs, NORML And Others Confirm Industry Appointments & Promotions

    Missed the first wave of cannabis investments? Don't make that mistake again.
    Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
    Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
     Just this year, the PotProfits portfolio has seen smoking-hot gains like:

    •  47.10% with $GTBIF
    •  40.23% with $TCNNF
    •  21.50% with $VFF

     But here's the kicker: Michael is about to release his next potential winners, and he's chomping at the bit to share these ticker symbols with you ASAP.

    Don't miss out on the green rush!

    Get the next $EEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EEX
    $OGI

    CompanyDatePrice TargetRatingAnalyst
    Organigram Global Inc.
    $OGI
    1/27/2026Buy
    Canaccord Genuity
    Organigram Global Inc.
    $OGI
    7/17/2024Speculative Buy
    Canaccord Genuity
    Organigram Global Inc.
    $OGI
    4/15/2024Neutral → Buy
    Alliance Global Partners
    Emerald Holding Inc.
    $EEX
    7/25/2023$7.20Buy
    Rosenblatt
    Emerald Holding Inc.
    $EEX
    4/27/2023$12.00Buy
    Maxim Group
    Organigram Global Inc.
    $OGI
    1/13/2023Hold → Buy
    Stifel
    Organigram Global Inc.
    $OGI
    1/12/2022Hold → Speculative Buy
    Canaccord Genuity
    Organigram Global Inc.
    $OGI
    1/12/2022$5.70 → $5.30Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EEX
    $OGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Organigram Global

    Canaccord Genuity initiated coverage of Organigram Global with a rating of Buy

    1/27/26 9:29:20 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity resumed coverage on OrganiGram

    Canaccord Genuity resumed coverage of OrganiGram with a rating of Speculative Buy

    7/17/24 12:18:49 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OrganiGram upgraded by Alliance Global Partners

    Alliance Global Partners upgraded OrganiGram from Neutral to Buy

    4/15/24 8:40:01 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EEX
    $OGI
    SEC Filings

    View All

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    2/18/26 10:40:13 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    2/10/26 7:41:44 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Organigram Global Inc.

    6-K - ORGANIGRAM GLOBAL INC. (0001620737) (Filer)

    2/3/26 11:10:05 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EEX
    $OGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Levin David Saul increased direct ownership by 0.63% to 290,998 units (SEC Form 5)

    5 - Emerald Holding, Inc. (0001579214) (Issuer)

    2/5/26 4:00:10 PM ET
    $EEX
    Real Estate

    EVP, Content & Commerce Puceta Danielle returned $103,405 worth of shares to the company (22,382 units at $4.62), decreasing direct ownership by 34% to 43,446 units (SEC Form 4)

    4 - Emerald Holding, Inc. (0001579214) (Issuer)

    1/8/26 4:09:33 PM ET
    $EEX
    Real Estate

    President, Connections Group Jouaneh Issa returned $409,064 worth of shares to the company (88,542 units at $4.62), decreasing direct ownership by 33% to 181,875 units (SEC Form 4)

    4 - Emerald Holding, Inc. (0001579214) (Issuer)

    1/8/26 4:07:21 PM ET
    $EEX
    Real Estate

    $EEX
    $OGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Organigram Announces C$65.2 Million BAT Private Placement Investment in Connection with the Acquisition of Sanity Group

    Organigram shares priced at average C$2.72 per share representing a combination of Top-Up Rights being exercised at C$2.34/share and shares issued in connection with Sanity acquisition priced at C$3.00/share. Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading global cannabis company, today announced that it has entered into a subscription agreement (the "Subscription Agreement") with BT DE Investments Inc. ( "BAT"), a wholly-owned subsidiary of British American Tobacco p.l.c. (NYSE:BTI), in connection with its previously announced proposed acquisition (the "Acquisition") of Sanity Group GmbH ("Sanity" or "Sanity Group"), including shares of Sanity ow

    2/19/26 6:00:00 AM ET
    $BTI
    $OGI
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Organigram Announces Proposed Acquisition of Sanity Group, a Leading German Cannabis Company

    Accretive Acquisition of Sanity Group Establishes Organigram as a Global Pure Play Cannabis Company with Leadership Positions in the World's Two Largest Federally Legal Cannabis Markets Organigram to acquire Sanity Group for up-front consideration of €113.4 million plus a maximum earnout of up to €113.8 million tied to financial performance. Proposed Acquisition of the Berlin‑based company unites two leaders in the largest federally legal cannabis markets, boosting commercial opportunities, strengthening access to best‑in‑class leadership, and expanding a valuable network of supply-chain partners. Sanity is achieving top-line growth. Annual net revenue increased from €9 million in

    2/18/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Reports First Quarter Fiscal 2026 Results

    Strong year-over-year growth supported by Canadian leadership and growing international sales, improving gross margin. Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its results for the first quarter ended December 31, 2025 ("Q1 Fiscal 2026" or "Q1"). Q1 FISCAL 2026 HIGHLIGHTS Gross Revenue: $97.3 million (+46% year-over-year). Net Revenue: $63.5 million (+49% year-over-year). International Revenue: $5.0 million (+51% year-over-year). Adjusted EBITDA2: $5.3 million (+273% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2

    2/10/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EEX
    $OGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, Connections Group Jouaneh Issa bought $47,800 worth of shares (10,000 units at $4.78), increasing direct ownership by 4% to 270,417 units (SEC Form 4)

    4 - Emerald Holding, Inc. (0001579214) (Issuer)

    6/9/25 4:03:06 PM ET
    $EEX
    Real Estate

    $EEX
    $OGI
    Leadership Updates

    Live Leadership Updates

    View All

    Organigram Announces Appointment of Chief Executive Officer

    Organigram Global Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), the parent company of Organigram Inc., a leading Canadian producer of cannabis, is pleased to announce that James Yamanaka, formerly Global Head of Strategy for British American Tobacco, has been appointed the Company's new Chief Executive Officer (CEO). Mr. Yamanaka is expected to assume the role effective on or about January 15, 2026. Mr. Yamanaka will also join the Company's board of directors when he assumes the role of Chief Executive Officer. Mr. Yamanaka is a seasoned executive, having spent more than 20 years at British American Tobacco, with extensive experience in strategy and general management across

    11/25/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emerald Holding, Inc. Appoints Vincenzo DiMaggio Chief Accounting Officer

    Emerald Holding, Inc. (NYSE: EEX) a leader in building dynamic, market-driven business-to-business (B2B) events and media platforms, today announced the appointment of Vincenzo ("Vince") DiMaggio as Chief Accounting Officer. In his new role, Vince brings more than 25 years of accounting leadership across both public and private companies. Most recently, he was SVP and Chief Accounting Officer at Stagwell Global, where he oversaw global accounting, reporting, and compliance for a diverse international portfolio. Previously, he was Global Controller and Chief Accounting Officer at Endeavor and held senior finance roles at Viacom Inc., and The New York Times Company. A CPA with expertise in

    9/29/25 8:30:00 AM ET
    $EEX
    Real Estate

    Emerald Holding, Inc. Appoints Danielle Puceta as Chief Digital Officer to Lead Digital Transformation and Innovation

    Emerald Holding, Inc. (NYSE:EEX) is excited to announce the appointment of Danielle Puceta as Chief Digital Officer (CDO), effective immediately. In this newly created role, Danielle will spearhead Emerald's digital strategy and business transformation, driving innovation and growth across the organization. As CDO, Danielle will oversee the expansion of Emerald's Event Tech platforms, lead-generation initiatives, and the integration of AI to enhance productivity and customer experiences. She will also champion product innovation to ensure Emerald remains at the forefront of the evolving B2B landscape. In addition to her new responsibilities, Danielle will continue as General Manager of El

    9/10/25 8:30:00 AM ET
    $EEX
    Real Estate

    $EEX
    $OGI
    Financials

    Live finance-specific insights

    View All

    Organigram Reports First Quarter Fiscal 2026 Results

    Strong year-over-year growth supported by Canadian leadership and growing international sales, improving gross margin. Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share1, is pleased to announce its results for the first quarter ended December 31, 2025 ("Q1 Fiscal 2026" or "Q1"). Q1 FISCAL 2026 HIGHLIGHTS Gross Revenue: $97.3 million (+46% year-over-year). Net Revenue: $63.5 million (+49% year-over-year). International Revenue: $5.0 million (+51% year-over-year). Adjusted EBITDA2: $5.3 million (+273% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2

    2/10/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram to Report First Quarter Fiscal 2026 Results on February 10, 2026

    Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 cannabis company by market share, announced today it will report earnings results for its first quarter fiscal 2026 ended December 31, 2025, on Tuesday, February 10, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 10, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://events.q4inc.com/analyst/430252525?pwd=WEt2KbHS To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call.

    2/3/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organigram Reports Record Fourth Quarter and Fiscal 2025 Results

    Record annual revenue, adjusted EBITDA1, and international sales. Organigram Global Inc (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), Canada's #1 recreational cannabis company by market share2, is pleased to announce record results for the fourth quarter and twelve months ended September 30, 2025 ("Q4 Fiscal 2025" or "Fiscal 2025"). All financial information in this press release is expressed in Canadian dollars ("$"). FOURTH QUARTER 2025 FINANCIAL HIGHLIGHTS Gross Revenue: $123.3 million (+76% year-over-year). Net Revenue: $80.1 million (+79% year-over-year). Adjusted Gross Margin1: $30.6 million or 38%. Adjusted EBITDA1: $9.8 million (+69% year-over-year). FISCAL 20

    12/16/25 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EEX
    $OGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    12/10/24 7:10:15 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    9/3/24 9:30:26 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Emerald Holding Inc. (Amendment)

    SC 13D/A - Emerald Holding, Inc. (0001579214) (Subject)

    2/15/24 5:04:16 PM ET
    $EEX
    Real Estate